AC Immune (ACIU)

• Market cap: $226M
• 1 day: 1.37%
• 5 days: -3.9%
• 1 month: -11.55%
• 3 months: -27.21%
• 6 months: -33.53%
• Year to date: -33.93%
• 1 year: 0.91%
• 5 years: -68.86%
• 10 years: -85.82%
• Sector: Healthcare
• Industry: Biotechnology

About: AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Employees: 122